Johnson & Johnson $JNJ Shares Bought by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 67.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 125,003 shares of the company’s stock after purchasing an additional 50,304 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in Johnson & Johnson were worth $25,870,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in JNJ. Abich Financial Wealth Management LLC purchased a new stake in shares of Johnson & Johnson during the third quarter valued at $26,000. Cresta Advisors Ltd. purchased a new position in Johnson & Johnson in the 4th quarter worth $26,000. DecisionPoint Financial LLC lifted its position in Johnson & Johnson by 104.2% during the 4th quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock worth $30,000 after acquiring an additional 75 shares during the period. Family CFO Inc acquired a new stake in Johnson & Johnson during the 4th quarter worth about $31,000. Finally, Bay Harbor Wealth Management LLC grew its stake in Johnson & Johnson by 49.0% during the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock valued at $31,000 after purchasing an additional 49 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Wells Fargo & Company raised their price objective on Johnson & Johnson from $240.00 to $263.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 15th. HSBC raised their price objective on Johnson & Johnson from $265.00 to $280.00 and gave the stock a “buy” rating in a research note on Tuesday, March 17th. Daiwa Securities Group raised their price objective on Johnson & Johnson from $237.00 to $246.00 and gave the stock an “outperform” rating in a research note on Thursday, April 16th. Citigroup raised their price objective on Johnson & Johnson from $274.00 to $285.00 and gave the stock a “buy” rating in a research note on Tuesday, April 7th. Finally, Barclays raised their price objective on Johnson & Johnson from $234.00 to $255.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 15th. Twenty equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $253.04.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson said its immunology drug nipocalimab was approved in China, expanding the company’s international growth opportunity and adding to its pipeline momentum. Reuters: Johnson & Johnson says nipocalimab approved in China
• Positive Sentiment: The company unveiled the Shockwave C2 Aero Coronary IVL Catheter, a next-generation device for calcified coronary artery disease, reinforcing growth in its medtech division and showing continued product innovation. Yahoo Finance: Johnson & Johnson (JNJ) Unveils Next-Gen Catheter for Coronary Artery Disease
• Positive Sentiment: Reports highlighting Johnson & Johnson as a defensive growth stock and a top long-term pick may be supporting sentiment, especially as investors look for steadier names amid market volatility. Insider Monkey: Why Johnson & Johnson (JNJ) Still Fits a Defensive Growth Case
• Neutral Sentiment: Several market commentaries and stock reports referenced J&J alongside other dividend and healthcare names, but these pieces did not provide new company-specific catalysts. Yahoo Finance: Johnson & Johnson Outperforms Broader Market

Johnson & Johnson Trading Up 1.0%

Shares of NYSE:JNJ opened at $231.69 on Friday. The stock has a market cap of $557.73 billion, a price-to-earnings ratio of 26.79, a PEG ratio of 2.25 and a beta of 0.27. Johnson & Johnson has a 52-week low of $149.04 and a 52-week high of $251.71. The business has a 50-day moving average price of $234.19 and a 200-day moving average price of $223.20. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.68 by $0.02. The firm had revenue of $24.06 billion for the quarter, compared to analyst estimates of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.Johnson & Johnson’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same period last year, the company earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Equities analysts predict that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th will be issued a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 2.3%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Tuesday, May 26th. Johnson & Johnson’s dividend payout ratio is 60.12%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.